Trials / Completed
CompletedNCT00962975
A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this open-label multicenter study the long-term effect of Pegasys monotherapy on pharmacodynamic HBV-related markers will be investigated in patients with chronic hepatitis B. Eligible patients will have completed treatment on another donor protocol (e.g. PP22512) and will receive Pegasys at an appropriate dose based on the standard of care (180mcg sc once weekly) for up to 48 weeks. Target sample size is \<100.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | peginterferon alfa-2a [Pegasys] | dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2009-08-20
- Last updated
- 2014-04-08
Locations
6 sites across 4 countries: United States, New Zealand, Singapore, Taiwan
Source: ClinicalTrials.gov record NCT00962975. Inclusion in this directory is not an endorsement.